Optimal management of metastatic bone disease Journal Articles

authors

• Major, Pierre

status

• published 

publication date

• 2007

has subject area

• 1110 Nursing (FoR)
• 1112 Oncology and Carcinogenesis (FoR)
• Bone Density Conservation Agents (MeSH)
• Bone Neoplasms (MeSH)
• Diphosphonates (MeSH)
• Drug Administration Schedule (MeSH)
• Humans (MeSH)
• Imidazoles (MeSH)
• Incidence (MeSH)
• Morbidity (MeSH)
• Nursing (Science Metrix)
• Pain (MeSH)
• Palliative Care (MeSH)
• Patient Selection (MeSH)
• Practice Guidelines as Topic (MeSH)
• Quality of Life (MeSH)
• Risk Factors (MeSH)
• Risk Reduction Behavior (MeSH)
• Treatment Outcome (MeSH)
• Zoledronic Acid (MeSH)

published in

• European Journal of Oncology Nursing  Journal

keywords

• BISPHOSPHONATES
• BREAST-CANCER PATIENTS
• COST-EFFECTIVENESS
• DOUBLE-BLIND
• LONG-TERM EFFICACY
• Life Sciences & Biomedicine
• MULTIPLE-MYELOMA
• Nursing
• Oncology
• PAMIDRONATE
• PREVENTION
• SKELETAL COMPLICATIONS
• Science & Technology
• ZOLEDRONIC ACID
• Zoledronic acid
• bisphosphonates
• bone pain
• skeletal-related events

Digital Object Identifier (DOI)

• 10.1016/j.ejon.2007.07.003

PubMed ID

• 17804294

start page

• S32

end page

• S37

volume

• 11